Search details
1.
Safety and Efficacy of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies Amubarvimab Plus Romlusevimab in Nonhospitalized Patients With COVID-19.
Ann Intern Med
; 176(5): 658-666, 2023 05.
Article
in English
| MEDLINE | ID: mdl-37068272
2.
ACTIV-2: A Platform Trial for the Evaluation of Novel Therapeutics for the Treatment of Early COVID-19 in Outpatients.
J Infect Dis
; 228(Suppl 2): S77-S82, 2023 08 31.
Article
in English
| MEDLINE | ID: mdl-37650231
3.
Pooling Different Placebos as a Control Group in a Randomized Platform Trial: Benefits and Challenges From Experience in the ACTIV-2 COVID-19 Trial.
J Infect Dis
; 228(Suppl 2): S92-S100, 2023 08 31.
Article
in English
| MEDLINE | ID: mdl-37650234
4.
Validity and Characterization of Time to Symptom Resolution Outcome Measures in the ACTIV-2/A5401 Outpatient COVID-19 Treatment Trial.
J Infect Dis
; 228(Suppl 2): S83-S91, 2023 08 31.
Article
in English
| MEDLINE | ID: mdl-37650237
5.
Phase 2 Safety and Antiviral Activity of SAB-185, a Novel Polyclonal Antibody Therapy for Nonhospitalized Adults With COVID-19.
J Infect Dis
; 228(2): 133-142, 2023 07 14.
Article
in English
| MEDLINE | ID: mdl-36661240
6.
Association Between Anterior Nasal and Plasma SARS-CoV-2 RNA Levels and Hospitalization or Death in Nonhospitalized Adults With Mild-to-Moderate COVID-19.
J Infect Dis
; 228(Suppl 2): S117-S125, 2023 08 31.
Article
in English
| MEDLINE | ID: mdl-37650230
7.
Long COVID After Bamlanivimab Treatment.
J Infect Dis
; 228(Suppl 2): S126-S135, 2023 08 31.
Article
in English
| MEDLINE | ID: mdl-37650236
8.
Statistical Challenges When Analyzing SARS-CoV-2 RNA Measurements Below the Assay Limit of Quantification in COVID-19 Clinical Trials.
J Infect Dis
; 228(Suppl 2): S101-S110, 2023 08 31.
Article
in English
| MEDLINE | ID: mdl-37650235
9.
Nasal and Plasma Severe Acute Respiratory Syndrome Coronavirus 2 RNA Levels Are Associated With Timing of Symptom Resolution in the ACTIV-2 Trial of Nonhospitalized Adults With Coronavirus Disease 2019.
Clin Infect Dis
; 76(4): 734-737, 2023 02 18.
Article
in English
| MEDLINE | ID: mdl-36210483
10.
One Week of Oral Camostat Versus Placebo in Nonhospitalized Adults With Mild-to-Moderate Coronavirus Disease 2019: A Randomized Controlled Phase 2 Trial.
Clin Infect Dis
; 77(7): 941-949, 2023 10 05.
Article
in English
| MEDLINE | ID: mdl-37279602
11.
Safety, Efficacy, and Pharmacokinetics of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies BMS-986414 (C135-LS) and BMS-986413 (C144-LS) Administered Subcutaneously in Non-Hospitalized Persons with COVID-19 in a Phase 2 Trial.
Pathog Immun
; 9(1): 138-155, 2024.
Article
in English
| MEDLINE | ID: mdl-38746756
12.
Statistical Challenges when Analyzing SARS-CoV-2 RNA Measurements Below the Assay Limit of Quantification in COVID-19 Clinical Trials.
medRxiv
; 2023 Mar 17.
Article
in English
| MEDLINE | ID: mdl-36993419
13.
Safety and efficacy of inhaled interferon-ß1a (SNG001) in adults with mild-to-moderate COVID-19: a randomized, controlled, phase II trial.
EClinicalMedicine
; 65: 102250, 2023 Nov.
Article
in English
| MEDLINE | ID: mdl-37855026
14.
Safety and Efficacy of Combined Tixagevimab and Cilgavimab Administered Intramuscularly or Intravenously in Nonhospitalized Patients With COVID-19: 2 Randomized Clinical Trials.
JAMA Netw Open
; 6(4): e2310039, 2023 04 03.
Article
in English
| MEDLINE | ID: mdl-37099295
15.
Comparative Pharmacokinetics of Tixagevimab/Cilgavimab (AZD7442) Administered Intravenously Versus Intramuscularly in Symptomatic SARS-CoV-2 Infection.
Clin Pharmacol Ther
; 112(6): 1207-1213, 2022 12.
Article
in English
| MEDLINE | ID: mdl-35797235
16.
Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19.
Nat Commun
; 13(1): 4931, 2022 08 22.
Article
in English
| MEDLINE | ID: mdl-35995785
17.
Predictors of SARS-CoV-2 RNA From Nasopharyngeal Swabs and Concordance With Other Compartments in Nonhospitalized Adults With Mild to Moderate COVID-19.
Open Forum Infect Dis
; 9(11): ofac618, 2022 Nov.
Article
in English
| MEDLINE | ID: mdl-36467293
18.
Emergence of SARS-CoV-2 escape mutations during Bamlanivimab therapy in a phase II randomized clinical trial.
Nat Microbiol
; 7(11): 1906-1917, 2022 11.
Article
in English
| MEDLINE | ID: mdl-36289399
19.
Bamlanivimab reduces nasopharyngeal SARS-CoV-2 RNA levels but not symptom duration in non-hospitalized adults with COVID-19: A Phase 2 Randomized Clinical Trial.
medRxiv
; 2021 Dec 21.
Article
in English
| MEDLINE | ID: mdl-34981077
20.
Publisher Correction: Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19.
Nat Commun
; 14(1): 333, 2023 Jan 19.
Article
in English
| MEDLINE | ID: mdl-36658128
Results
1 -
20
de 20
1
Next >
>>